Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYB005
- Development stage
- Preclinical
- Lead developer
- Cybin
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
CYB005 is a preclinical phenethylamine derivative being developed by Cybin for the treatment of central nervous system (CNS) disorders. The program focuses on novel molecules administered at non-hallucinogenic doses and aims to address treatment-resistant psychiatric conditions. These compounds are designed as non-hallucinogenic neuroplastogens and act primarily as serotonin receptor agonists—specifically targeting the serotonin 5-HT2A receptor and potentially other subtypes such as 5-HT1A and 5-HT2C receptors. The goal is to provide therapeutic benefits without the hallucinogenic effects associated with classic psychedelics[1][2][7]. Cybin has received a U.S. composition of matter patent for lead candidates in this program[1].
- Other names
- CYB005CYB-005CYB 005
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on CYB005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYB005.